Trial Claims First All Oral Cure for Advanced Hep C
April 23, 2012
Boehringer Ingelheim’s all oral Hepatitis C drugs cured 82 percent of patients with the most common type of Hepatitis C in mid-stage trials. In addition, these drugs exhibited the potential to cure people with cirrhosis.
Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial
By Makiko Kitamura on April 19, 2012
Boehringer Ingelheim GmbH said its experimental hepatitis C oral treatment cleared the virus in as many as 82 percent of patients in a study.
The mid-stage Sound-C2 trial followed 362 patients who hadn’t received other treatments before taking the Ingelheim, Germany-based drugmaker’s BI 201335 protease inhibitor and BI 207127 polymerase inhibitor, either as a two-drug combination or along with a third drug, ribavirin.
Researchers reported an 82 percent cure rate among patients with the most common type of hepatitis C after 28 weeks of treatment, Boehringer said today at the European Association for the Study of the Liver annual meeting in Barcelona. Among all patients studied, 68 percent were cured. The study contrasts with other studies being presented at the conference with much smaller patient groups.
Continue reading this entire article: